Rediscover healing that remains ahead of its time.

Bioengineered with living cells to transform wounds from chronic to acute, Apligraf® is backed by unmatched clinical evidence in healing VLUs and DFUs.¹⁻⁸

> INNOVATION THAT WON'T BE IGNORED

DFU=diabetic foot ulcer VLU=venous leg ulcer

Organogenesis



Apligraf[®] has unmatched clinical and real-world evidence in both VLUs and DFUs.

Randomized controlled trials^{9,10}

- Strongest method for proving efficacy and safety
- Required to obtain FDA approval

Real-world observational studies^{9,10}

- Provide evidence of health benefit in real-world use
- Demonstrate effectiveness in patients with significant comorbid conditions

In randomized controlled trials, Apligraf was proven to:

- Heal more VLUs faster than SOC^{2,8}
- Heal more DFUs faster than SOC⁶

In observational comparative effectiveness studies,* Apligraf was proven to:

- Heal more VLUs faster than Oasis®, TheraSkin®, and PriMatrix®³⁻⁵
- Heal more DFUs faster than EpiFix^{®7}

*Effectiveness is the extent to which an intervention produces an overall health benefit in routine clinical practice (real-world situations). Effectiveness studies do not establish efficacy or comparative superiority. Based on data obtained from a large wound care-specific Electronic Medical Record (EMR) database (WoundExpert®, Net Health, Pittsburgh, PA).

Health economic analysis

- · Supports improvement of patients' quality of life
- Provides evidence of cost-savings and cost-effectiveness

In health economic analyses, use of Apligraf:

- Improved healing of VLUs, resulting in lower treatment costs¹¹
- Helped to reduce complications of DFUs, resulting in reduction of healthcare costs¹²

SOC=standard of care

Unsurpassed coverage for patients—regardless of their insurance.⁺

100%

of Medicare contractors cover Apligraf treatment for VLUs and DFUs⁸



of commercial medical policies cover Apligraf treatment for VLUs and DFUs⁸

The coverage information provided shall not be construed as a statement, promise, or guarantee that reimbursement will be received. Reimbursement requirements are subject to change at any time. Check with your local payer regularly.

[†]Insurance coverage varies by payer and is subject to change at any time. Confirm with your current applicable payer policies for up-to-date Apligraf coverage requirements and policies.

	VLU coverage	DFU coverage
Aetna	1	1
Anthem	\checkmark	\checkmark
BCBS Federal Employee Program	\checkmark	\checkmark
BCBS Highmark	\checkmark	\checkmark
Cigna	\checkmark	\checkmark
Excellus	\checkmark	\checkmark
Humana	\checkmark	\checkmark
Medica		
UnitedHealthcare	\checkmark	 Image: A set of the set of the

Learn more about the gold standard that heals faster at Apligraf.com

Please refer to the included Apligraf package insert for complete prescribing information and contraindications.

References: 1. Stone RC, et al. *Sci Transl Med.* 2017;9(371). doi:10.1126/scitranslmed.aaf8611 **2.** Apligraf [package insert]. Canton, MA: Organogenesis Inc; 2017. **3.** Marston WA, et al. *Wound Repair Regen.* 2014;22(3):334-340. **4.** Treadwell T, et al. *Adv Wound Care.* 2018;7(3):69-76. **5.** Sabolinski ML, et al. *J Comp Eff Res.* 2018;7(8):797-805. **6.** Veves A, et al. *Diabetes Care.* 2001;24(2):290-295. **7.** Kirsner RS, et al. *Wound Repair Regen.* 2015;23(5):737-744. **8.** Data on file. Organogenesis Inc: **9.** Carter MJ, et al. *Adv Skin Wound Care.* 2009;22(7):316-324. **10.** Horn SD. JAMA. 2006;296(22):2731-2732. **11.** Schonfeld WH, et al. *Wound Repair Regen.* 2000;8:251-257. **12.** Rice JB, et al. *J Med Econ.* 2014;17(5):347-356.



S.A. 01/2020 Jemark of Smith & Nephew, Inc. s a registered trademark of Integra LifeSciences Corp.

